Excalipoint Therapeutics Secures $68.7M Funding to Pioneer Next-Generation T-Cell Therapies
Published: 01 Apr 2026
Author: Precedence Research
Excalipoint Therapeutics, a biotechnology company engaged in the development of next-generation T-cell engager therapies for cancer and autoimmune diseases, has announced the successful completion of an oversubscribed seed financing round totaling $68.7 million.
This funding will be used to accelerate the development of the company’s proprietary technology platforms and advance its pipeline of innovative and differentiated T-cell engager programs, aimed at addressing unmet medical needs in oncology and immunology. The substantial seed round highlights strong investor confidence in Excalipoint’s scientific approach and its potential to transform treatment options for patients worldwide.
The company initially raised $41 million in seed funding at its August 2025 inception, co-led by HSG, Apricot Capital, and Yuanbio Venture Capital, with participation from 5Y Capital, Co-Win Ventures, Med-Fine Capital, and Hony Capital, marking one of the largest early-stage financings for a Chinese biotech firm. After achieving full operational status and significant clinical progress in six months, Excalipoint secured a $27.7 million extension round co-led by MPCi and Centurium Capital, with contributions from LAV, Eisai Innovation Inc, and existing investors Apricot Capital and 5Y Capital.
According to the Precedence Research, the T-cell Engagers Market size was valued at USD 7.70 billion in 2025 and is expected to reach USD 32.53 billion by 2035, expanding at a CAGR of 15.50% between 2026 and 2035, driven by rising investments in R&D of cell therapies.
“Excalipoint is developing a proprietary pipeline and three powerful technology platforms to position our company as a true innovation powerhouse and developer of T-cell engagers,” said Lei Fang, Ph.D., Co-Founder, Chairman and Chief Executive Officer, Excalipoint Therapeutics.
“MPCi is deeply engaged in healthcare, focusing on science-driven innovative enterprises with core technological barriers. Excalipoint is our highly recognized next-generation TCE innovation powerhouse,” said David Su, Founding Managing Partner, MPCi.
Excalipoint Therapeutics Journey
Excalipoint Therapeutics is a clinical-stage biotechnology company. It is mainly dedicated to the discovery and development of next-generation innovative T-cell engager therapies to unmet medical needs globally. The company is also dedicated to the development of novel T-based therapeutics with greater differentiation and stronger clinical potential to overcome treatment barriers of existing therapies.
Exalipoint’s Future Pipeline Programs
- EXP011 (CTM012) – A tri-specific antibody targeting DLL3, CD3, and 4-1BB, developed for small cell lung cancer, neuroendocrine tumors, and other DLL3 malignancies.
- EXP012 (CTM013) – A tri-specific antibody targeting CDH17, CD3, and 4-1BB, being developed to treat colorectal, gastric, and pancreatic cancers.
- EXP016 – A tri-specific antibody leveraging the TOPAbody platform designed to target solid tumors with unmet medical need.
- EXP017 – A multi-specific antibody developed using the Immune Shield platform aimed at addressing limitations of the tumor microenvironment.
- EP101 – A molecule enhanced with the Pro-TCE platform technology designed to enable targeting of tumor-associated antigens.
- EXP015 – A tri-specific antibody derived from the TOPAbody platform targeting IgG-associated diseases in immunology.